A PROTAC‐Based Cuproptosis Sensitizer in Lung Cancer Therapy
Advanced Materials · 2025-08 · 37 (34)
DOI: 10.1002/adma.202501435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 11.06.2025. Verfasst von Yu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Tongji Universi…. Hauptthemen laut MEDLINE: Apoptosis, Lung Neoplasms, Copper, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
As an autonomous form of regulated cell death, cuproptosis depends on copper (Cu) and mitochondrial metabolism. However, the principle metabolic pathway known as glycolysis (Warburg effect) and high glutathione (GSH) levels of tumor cells inevitably lead to suboptimal efficacy in cuproptosis. Hence, depleting the endogenous GSH within tumors and shifting from glycolysis to mitochondrial respiration are crucial factors for augmenting cuproptosis. In this study, a proteolysis targeting chimera (PROTAC)‐based cuproptosis sensitizer (CuS‐MD@CS) is innovatively constructed, which not only can induce cuproptosis and reactive oxygen species production via copper ions but also can regulate the expression of p53 protein via PROTACs through the ubiquitin‐proteasome system in tumor cells, thus achieving endogenous GSH depletion and a shift from glycolysis to mitochondrial respiration, making cancer cells more sensitive to cuproptosis. Importantly, in vitro and in vivo experiments have verified that CuS‐MD@CS effectively targets A549 cells and suppresses tumor growth through cuproptosis and apoptosis, exhibiting promising therapeutic responses. The novel PROTAC‐based cuproptosis sensitizer CuS‐MD@CS provides a new strategy for sensitizing cuproptosis and offers new hope for effective lung cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Tongji University, Shanghai, 200092, China.
- Department of Clinical Laboratory, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.
ORCID-Profile: Shuo Shi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Shanghai Municipal Health Commission
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Wang, Y., Yao, X., Lu, Y., Ruan, J., Yang, Z., Wang, C., Yang, N., Gao, Y., & Shi, S. (2025). A PROTAC‐Based Cuproptosis Sensitizer in Lung Cancer Therapy. Advanced Materials, 37(34). https://doi.org/10.1002/adma.202501435
Vancouver
Wang Y, Yao X, Lu Y, Ruan J, Yang Z, Wang C, et al. A PROTAC‐Based Cuproptosis Sensitizer in Lung Cancer Therapy. Advanced Materials. 2025;37(34). doi:10.1002/adma.202501435
BibTeX
@article{Wang2025,
author = {Wang, Yu and Yao, Xiaoyang and Lu, Yingying and Ruan, Juan and Yang, Zhao and Wang, Chunhui and Yang, Niantong and Gao, Yan and Shi, Shuo},
title = {A PROTAC‐Based Cuproptosis Sensitizer in Lung Cancer Therapy},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {34},
doi = {10.1002/adma.202501435}
}
EUVIMED